AtriCure beats Q2 estimates by 500%, raises 2026 guidance

AtriCure swung to a profit in the second quarter as revenue rose 13% to $154 million, driven by its pain management and appendage management franchises, and the company raised its full-year outlook on expanding margins.

"These results reinforce the progress we are making to improve profitability," Chief Executive Mike Carroll said on the earnings call. The company generated $27 million in adjusted EBITDA and $9 million in net income, compared with a net loss of $6.2 million a year earlier.

Earnings per share came in at $0.18, six times the $0.03 consensus estimate compiled by Zacks, and swung from a loss of $0.02 per share in the same quarter last year. Gross margin expanded 270 basis points to 77.2%, driven by favorable product mix from newer devices such as the CryoSphere Max probe and AtriClip Mini family. The company now expects full-year revenue of $602 million to $610 million, up from prior guidance, and raised adjusted EBITDA guidance to $85 million to $89 million.

The results underscore a broader shift underway at AtriCure: the company is transitioning from a growth-at-all-costs medtech into a profitable operator with a pipeline of clinical catalysts that could expand its addressable market by hundreds of thousands of patients. Two landmark trials — BOX No AF, which has surpassed 50% enrollment with more than 500 patients, and LEAPS, which is following more than 6,500 patients — are designed to prove that prophylactic ablation and left atrial appendage management reduce complications in cardiac surgery patients without a history of atrial fibrillation. Data readouts are expected in the first half of 2027.

Pain Management Leads Growth, Sternotomy Emerging

Pain management revenue surged 28% to $27 million in the U.S., making it the fastest-growing segment for the sixth consecutive quarter. The CryoSphere Max probe now accounts for about 75% of U.S. pain management sales, and the company added accounts at a robust pace during the quarter. While thoracic procedures still represent the majority of use, sternotomy is emerging as a growth driver, with roughly 100 accounts now evaluating the technology for cardiac surgery recovery.

The newly launched CryoXT probe, designed for below-knee amputation procedures, contributed a small but growing amount of revenue. AtriCure presented early clinical results at the Society for Vascular Surgery annual meeting in June, and management expects CryoXT to contribute more meaningfully in the second half of the year. The company has hired dedicated extremity sales representatives to support the launch.

Appendage Management Faces First Real Competitive Test

Appendage management revenue rose 14% to $52 million in the U.S., with the AtriClip Flex Mini and Pro Mini devices now accounting for 45% of total appendage management sales. Surgeon feedback on the smaller-profile devices has been positive, and the company plans to launch the Mini platform in Europe later this year.

The competitive landscape is shifting. Larger medtech companies have entered the left atrial appendage management market, a development Carroll characterized as validation of the opportunity. AtriCure's defense rests on three pillars: continuous product innovation — including a smaller AtriClip version due by year-end and the V Clip Mini expected in late 2027 — a clinical compendium of more than 100 peer-reviewed papers covering 20,000 patients, and a field team of more than 500 commercial and professional education staff. The company has incorporated expected trialing of competitive products into its second-half guidance.

Open Ablation Gains From Quality Metric Change

Open ablation revenue increased 12% to $41 million, supported by the Encompass Clamp, now four years into its full U.S. launch and still gaining traction in international markets. A new Society of Thoracic Surgeons quality metric on concomitant atrial fibrillation treatment is expected to drive further adoption, as similar quality measures have historically been powerful catalysts in cardiac surgery.

Minimally invasive ablation remained under pressure at $6 million, as the market continues to favor pulsed-field ablation catheters for standalone procedures. AtriCure said referral patterns for hybrid therapy have stabilized in a small subset of accounts but need to broaden before the franchise can return to growth.

International Markets Show Mixed Results

International revenue of $28 million grew 10% on a reported basis, with Asia Pacific rebounding from a soft first quarter. European sales rose 7%, held back by weakness in the United Kingdom and Germany. The U.K. market remained sequentially flat due to reimbursement changes affecting the CryoSphere probe, though recent positive news on Encompass Clamp reimbursement may provide a partial offset.

Investor Implications

AtriCure shares trade on the Nasdaq under the ticker ATRC. The company generated $22 million in cash during the quarter, ending with $168 million in cash and investments, and expects positive cash generation for the remainder of the year. With adjusted EBITDA margins approaching 14% and two pivotal clinical trials approaching data readouts, the next 12 to 18 months represent a potential inflection point for both the top line and the investment thesis. The BOX No AF trial alone, if positive, could expand AtriCure's addressable market to include the roughly 500,000 U.S. cardiac surgery patients annually who currently do not receive prophylactic AFib treatment.

This article is for informational purposes only and does not constitute investment advice.